Avantor Inc (AVTR)
Drugs • Health Care
Financial Metrics
Price to Earnings-16.3x
Revenue Growth (1Y)-1.57%
Debt to Equity0.66x
Strengths
Valuation
Avantor Inc is undervalued
News
All
Press Releases
News
Filings

July 29, 2026 Avantor® Reports Second Quarter 2026 Results

July 29, 202610-Q Quarterly Report for 2026 Q2

July 14, 2026 Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product

July 01, 2026 Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026

May 19, 2026 Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory

April 29, 2026 Avantor® Reports First Quarter 2026 Results

April 29, 202610-Q Quarterly Report for 2026 Q1

April 23, 2026 Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer

April 21, 2026 Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing

April 13, 2026 Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility

April 03, 2026 Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026

April 01, 2026 Avantor® Announces CFO Transition

March 25, 2026EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks

March 04, 2026Looking For A Rebound? China Tech and Emerging Markets Top Oversold List

February 11, 2026Software Slump Resumes, Bitcoin Plunges To $66,000: What's Moving Markets Wednesday?

February 11, 2026Avantor Falls To Critical Levels As CEO Signals Investment Year Amid Soft Guidance

February 11, 2026 Avantor® Reports Fourth Quarter and Full Year 2025 Results

February 11, 202610-K Annual Report for 2025 FY

January 12, 2026 Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026

January 05, 2026 Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Avantor Investors Have Opportunity to Lead Class Action Lawsuit

December 26, 2025Deadline Soon: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

December 21, 2025SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Avantor

December 18, 2025 Avantor® Appoints Simon Dingemans to its Board of Directors

December 04, 2025 Avantor® Appoints Sanjeev Mehra to its Board of Directors

December 03, 2025AVTR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Avantor, Inc. Investors

November 25, 2025Labaton Keller Sucharow LLP Files Securities Class Action Against Avantor, Inc. and Certain of Its Executives

November 25, 2025 Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology

November 19, 2025 Avantor® Expands Centralized Service Center Model with Opening of Boston-Area Facility

November 18, 2025Stock Market Today: Dow Jones, S&P 500 Futures Tumble—Home Depot, Axalta Coating Systems, Molina Healthcare In Focus

November 10, 2025Deadline Alert: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

November 10, 2025 Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

November 07, 2025Deadline Approaching: Avantor, Inc. (AVTR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith

November 06, 2025Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action

November 06, 2025SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Avantor

November 05, 2025Law Offices of Frank R. Cruz Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action

November 05, 2025Law Offices of Howard G. Smith Encourages Avantor, Inc. (AVTR) Shareholders To Inquire About Securities Fraud Class Action

November 03, 2025Securities Fraud Investigation Into Avantor, Inc. (AVTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

October 29, 2025Avantor Struggles With Soft Demand But Backs Long-Term Value Through Buyback

October 29, 202510-Q Quarterly Report for 2025 Q3

August 11, 2025Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts

August 11, 2025Activist Investor to Push Avantor to Make Changes or Sell Itself

August 10, 2025Activist Investor to Push Avantor to Make Changes or Sell Itself

August 01, 2025Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure

August 01, 202510-Q Quarterly Report for 2025 Q2

May 28, 2025GREGORY SUMME Takes a Bullish Stance: Acquires $375K In Avantor Stock

May 23, 2025Avantor Board Member Makes $253K Stock Purchase

April 30, 2025Eye On Growth: Jonathan Peacock Adds $103K Of Avantor Stock To Portfolio

April 29, 2025Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: 'We Wrongly Assumed...'

April 28, 2025Avantor Analysts Cut Their Forecasts After Q1 Results

April 25, 2025Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift

April 25, 202510-Q Quarterly Report for 2025 Q1

February 20, 2025Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

February 09, 2025Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

February 07, 2025Wall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?

February 07, 2025Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025

February 07, 202510-K Annual Report for 2024 FY

October 25, 202410-Q Quarterly Report for 2024 Q3

July 26, 202410-Q Quarterly Report for 2024 Q2

April 26, 202410-Q Quarterly Report for 2024 Q1

February 14, 202410-K Annual Report for 2023 FY

October 27, 202310-Q Quarterly Report for 2023 Q3

July 28, 202310-Q Quarterly Report for 2023 Q2

April 28, 202310-Q Quarterly Report for 2023 Q1

February 14, 202310-K Annual Report for 2022 FY

October 28, 202210-Q Quarterly Report for 2022 Q3

July 29, 202210-Q Quarterly Report for 2022 Q2

April 29, 202210-Q Quarterly Report for 2022 Q1

February 11, 202210-K Annual Report for 2021 FY

October 29, 202110-Q Quarterly Report for 2021 Q3
A. Company Overview
Avantor, Inc. is recognized as a prominent global provider of essential products and services that support research and operational needs within key sectors such as biopharma, healthcare, education, government, and advanced technologies and applied materials. Established in 1904 with the founding of the J.T. Baker Chemical Company, Avantor has its roots deeply embedded in the scientific community and has evolved through significant expansions and mergers. The company was incorporated in Delaware in May 2017 in anticipation of its acquisition of VWR, and it became publicly traded on the New York Stock Exchange in May 2019.
Avantor operates with a clear mission: to advance science and create solutions that contribute to a better world. This commitment manifests in the company’s support for customers from the initial stages of research through to large-scale manufacturing, ensuring a reliable supply of mission-critical products and services.
B. Business Segments
Avantor divides its operations into geographic segments, specifically: the Americas, Europe, and AMEA (Africa, Middle East, Asia). In late 2023, it was announced that the company would transition to two primary business segments effective January 1, 2024. These segments will focus on Lab Solutions and Bioscience Production.
The two new business segments reflect a consolidated approach to meeting customer needs and streamline operations across the various fields in which the company is involved. The three original geographic segments allowed Avantor to capture market dynamics and customer demands tailored to their specific regions.
C. Products and Services
Avantor's extensive product and service portfolio caters to diverse scientific and industrial requirements. This includes:
- Materials & Consumables: This category encompasses ultra-high purity chemicals, lab supplies, formulated silicone materials, customized excipients, and various research and clinical trial kits among others. Significant portions of Avantor’s offerings are proprietary, ensuring high standards for quality and purity.
- Equipment & Instrumentation: Avantor provides a range of advanced equipment including filtration systems, analytical instruments, and biological safety cabinets, all tailored to meet regulatory standards pertinent to the industries served.
- Services & Specialty Procurement: The company offers an array of specialized services that enhance laboratory operations, including logistical support, procurement, and tailored scale-up services for biopharmaceutical materials.
These products and services form the backbone of Avantor's business model, with over 85% of net sales derived from recurring product offerings.
D. Customers
Avantor boasts a diversified customer base comprising over 300,000 client locations in more than 180 countries. Approximately 40% of the company’s net sales in 2023 were generated from long-standing customers with which it has maintained relationships for over 15 years. This deep-rooted customer loyalty is indicative of Avantor's commitment to quality service and products.
The company's approach to customer relationship management aims to ensure a nuanced understanding of customer needs while providing the necessary support and innovation to meet evolving market demands.
E. Suppliers
The supplier network of Avantor consists of both proprietary products developed in-house and third-party products sourced from a wide range of global suppliers. The company fosters long-term relationships with many suppliers, some of which span more than two decades. These partnerships often include contracts that may involve exclusivity provisions or collaboration on product development, thereby enhancing the value offering provided to customers.
F. Sales Channels
Avantor utilizes a multifaceted sales strategy that includes direct sales through a trained global sales force, e-commerce platforms, and targeted catalogs. A notable feature of Avantor's operations is its digital e-commerce platform, Avantor ScienceCentral, which streamlines the purchasing process and integrates analytics to enhance customer experience.
In 2023, approximately 75% of all transactions occurred digitally, demonstrating a strong inclination towards adopting technology within the sales framework. This e-commerce approach has improved access to products and services while offering bespoke solutions to customer challenges.
G. Infrastructure
Avantor maintains a vast operational infrastructure with over 200 facilities worldwide, including 45 manufacturing plants that comply with current good manufacturing practices (cGMP). The company’s facilities are strategically located to leverage supply chain efficiencies while ensuring timely delivery and compliance with regulatory standards across various regions.
The firm also operates numerous innovation centers aimed at fostering collaboration with clients and customizing solutions for complex requirements. The laboratories and manufacturing facilities are equipped with cutting-edge technologies that support a flexible manufacturing environment capable of adapting to different production scales.
H. Information Technology
The company employs a sophisticated suite of Enterprise Resource Planning (ERP) systems that support standardized operations while offering insight into business processes. The global web infrastructure enables seamless integration with customers and suppliers, allowing rapid adaptability to new technological requirements and challenges.
I. Competition
Avantor operates in a highly competitive and fragmented market landscape that includes a range of regional and global providers. The competitive advantages of Avantor rest on its comprehensive product line, customization capabilities, exceptional service delivery, and a robust online shopping experience that supports customer needs.
The ability to adapt to customer demands and regulatory environments is crucial in maintaining a competitive edge in the life sciences sector. Avantor’s focus on product quality, customer intimacy, and broad market access position it favorably against competitors in the industry.
Stock Infos
SectorHealth Care
IndustryDrugs
CEOMichael Stubblefield
Dividends

Biotechnology
Avantor provides critical materials and services for biopharmaceuticals and healthcare research, including ultra-high purity chemicals and specialized laboratory supplies, which are essential in biotechnology applications.

Pharmaceutical Companies
The company supports the pharmaceutical sector through its extensive product offerings, including customized excipients and clinical trial kits tailored to the needs of drug development and manufacturing.

Medical Technology
Avantor supplies advanced equipment and instrumentation such as analytical instruments and filtration systems that meet regulatory standards in medical technology and laboratory environments.

Biomedical Research Labs
With its robust support for research needs, including tailored services for scale-up in biopharma, Avantor caters specifically to biomedical research labs, facilitating advancements in scientific studies.

Chemical Manufacturing
Avantor is a significant provider of ultra-high purity chemicals and specialty chemicals, integral to various research and industrial processes, positioning it firmly within the chemical manufacturing sector.

Distribution Network
Avantor has established a robust and efficient distribution network that ensures timely delivery of critical products, enhancing customer satisfaction and loyalty while creating a logistical advantage over smaller competitors.

Intangible Assets
Avantor Inc. possesses a strong portfolio of patents and proprietary technologies that enhance its product offerings, making it difficult for competitors to replicate their innovations and market position.
TMO
Thermo Fisher Scientific Inc
DHR
Danaher Corp
A
Agilent Technologies Inc
WAT
Waters Corp
BIO.B
Bio Rad Laboratories Inc B
ILMN
Illumina Inc
CRL
Charles River Laboratories International Inc
TECH
Bio-Techne Corp
AVNT
Avient Corp
MTD
Mettler-Toledo International Inc
PACB
Pacific Biosciences of California Inc
MEDP
Medpace Holdings Inc